載入...
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...
Na minha lista:
| 發表在: | JAMA Netw Open |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Medical Association
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7804917/ https://ncbi.nlm.nih.gov/pubmed/33433598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33441 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|